Roivant Sciences (NASDAQ:ROIV) Director Melissa Epperly Sells 17,750 Shares of Stock

Posted by on Jul 1st, 2026

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) Director Melissa Epperly sold 17,750 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $34.38, for a total value of $610,245.00. Following the completion of the sale, the director owned 16,474 shares of the company’s stock, valued at approximately $566,376.12. This trade represents a 51.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roivant Sciences Trading Down 1.0%

ROIV stock traded down $0.36 during trading hours on Wednesday, hitting $35.03. 4,370,640 shares of the stock traded hands, compared to its average volume of 6,139,927. The stock has a 50-day simple moving average of $29.88 and a 200 day simple moving average of $27.02. The company has a market cap of $25.20 billion, a P/E ratio of -58.38 and a beta of 1.13. Roivant Sciences Ltd. has a one year low of $10.70 and a one year high of $35.90.

Roivant Sciences (NASDAQ:ROIV – Get Free Report) last issued its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The firm had revenue of $2.52 million for the quarter, compared to analysts’ expectations of $3.41 million. During the same period in the previous year, the business earned ($0.29) earnings per share. Analysts forecast that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Institutional Trading of Roivant Sciences

Hedge funds have recently bought and sold shares of the company. SBI Securities Co. Ltd. boosted its holdings in shares of Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after buying an additional 1,166 shares during the period. Allworth Financial LP increased its position in shares of Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in shares of Roivant Sciences in the 4th quarter valued at approximately $47,000. Parallel Advisors LLC lifted its position in shares of Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after acquiring an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC boosted its stake in Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after purchasing an additional 2,665 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on ROIV. Guggenheim increased their target price on shares of Roivant Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, TD Cowen raised their price objective on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.59.

Read Our Latest Report on Roivant Sciences

About Roivant Sciences

(Get Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.

Read More

Insider Buying and Selling by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.